The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...

A systemic trend analysis of young onset esophageal cancer in American population, 2012-2021. Comparison of capecitabine plus oxaliplatin (CAPOX) vs paclitaxel plus carboplatin (PC) as chemotherapy in ...

Ascidian Therapeutics, a company developing RNA rewriting (or RNA exon editing) technology, announced a research collaboration and licensing agreement with Roche for the discovery and development of ...

Beijing Zhongke Journal Publising Co. Ltd. This study is led by Professor Zhenghe Li (State Key Laboratory of Rice Biology and breeding, Institute of Biotechnology, Zhejiang University, Hangzhou, ...

Researchers from the Icahn School of Medicine at Mount Sinai have shed valuable light on the nuanced functions and intricate regulatory methods of RNA editing, a critical mechanism underlying brain ...

Suggested Citation: "1 Introduction." National Academies of Sciences, Engineering, and Medicine. 2024. Charting a Future for Sequencing RNA and Its Modifications: A New Era for Biology and Medicine.

Hello, and welcome to Wave Life Sciences 2025 Research Day. [Operator Instructions] Also, as a reminder, this conference is being recorded today. I will now turn the call over to Kate Rausch, Vice ...

DNA is the backbone of the genetic code so, logically, decoding and understanding the genetic sequence along with epigenetic modifications came first. Yet, RNA and the emerging field of ...

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

ProQR Therapeutics advances RNA editing pipeline with upcoming CTA filing for AX-0810, while enhancing leadership and maintaining strong finances. ProQR Therapeutics N.V. announced significant ...